Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

201. Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms

Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms Coyle D, Cranney A, Tugwell P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) ) (CEE-MPA) and with no therapy. As a second-line therapy, NA-EE was assumed to be used after a woman was no longer compliant after 6 months of a first-line therapy. NA-EE was compared with no second-line therapy and with CEE-MPA as second-line therapy. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of 50-year-old menopausal women. Setting The study setting was primary care. The economic study

2003 NHS Economic Evaluation Database.

202. Menopausal hormone replacement therapy and risk of ovarian cancer. (Abstract)

Menopausal hormone replacement therapy and risk of ovarian cancer. The association between menopausal hormone replacement therapy and ovarian cancer is unclear.To determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk.A 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program.Twenty-nine US (...) clinical centers.A total of 44 241 postmenopausal women (mean age at start of follow-up, 56.6 years).Incident ovarian cancer.We identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6; 95% confidence interval [CI], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian

2002 JAMA

203. Menopausal Combined Hormone Therapy Update

Menopausal Combined Hormone Therapy Update [46] Menopausal Combined Hormone Therapy Update | Therapeutics Initiative Independent Healthcare Evidence > > [46] Menopausal Combined Hormone Therapy Update The Women’s Health Initiative (WHI) trial is a striking example of how scientific evidence can improve prescribing practice. Therapeutics Letter 30 reviewed the evidence on hormone replacement therapy in 1999. Evidence then available showed that long-term estrogen/progestin therapy to prevent (...) cardiovascular disease for menopausal women with previous myocardial infarction would cause more harm than good. This conclusion was based on data from the Heart and Estrogen/Progestin Replacement Study (HERS) randomized controlled trial (RCT). In July 2002 the follow-up of the HERS trial (HERS II) and the WHI were published. These two trials strengthen the evidence against using combined hormone therapy to prevent cardiovascular disease. WHI/HERS II details Population of women: WHI enrolled 16,608 healthy

2002 Therapeutics Letter

204. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials

Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials Kronenberg F, Fugh-Berman A Authors' objectives To review studies of complementary and alternative medicines (CAM) used for menopausal symptoms. Searching MEDLINE (from January 1966 (...) , red clover, dong quai, evening primrose oil, ginseng and Chinese herb mixture), dietary phytoestrogens (soy and soy extracts) and other CAM therapies (vitamin E, behavioural therapies, wild yam and progesterone creams). Participants included in the review Studies investigating women with menopausal symptoms were eligible. Studies examining single symptoms or conditions that are clearly associated with menopause were excluded. Outcomes assessed in the review The inclusion criteria were not defined

2002 DARE.

205. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. (Abstract)

Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Hormone replacement therapy (HRT) is commonly prescribed to treat menopausal symptoms and to prevent post-menopausal bone loss. However, many women are concerned about hormonal replacement therapy because they believe that such treatment will result in weight gain. The effect of HRT on weight and body fat distribution has not yet been examined in systematic (...) between those using oestrogen/progestogen and non-HRT users (-0.50, 95% CI -1.06, 0.06). Insufficient data exist to enable meta-analysis of the effect of HRT on waist-hip ratio, fat mass or skinfold thickness.There is evidence of no effect of unopposed oestrogen or combined oestrogen on body weight, indicating that these regimens do not cause extra weight gain in addition to that normally gained at menopause. (ABSTRACT TRUNCATED)

2000 Cochrane

206. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Full Text available with Trip Pro

Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Due to their known effects on bone metabolism, Vitamin D and related compounds have been proposed for the prevention of osteoporosis and fractures.To determine the effects of supplementation with Vitamin D or a Vitamin D analogue in the prevention of fractures of the axial and appendicular skeleton in elderly men or women with involutional or post-menopausal osteoporosis.We (...) , or the administration of calcium supplements, with fracture as an outcome, in elderly men or women with involutional or post-menopausal osteoporosis.Two reviewers independently assessed trial quality, by use of a seven item scale, and extracted data. Additional information was sought from trialists. Where possible the data were pooled.Fourteen trials recording 13 different comparisons were included. In the only trial of Vitamin D alone, protection against hip fracture was not confirmed. Two regimens, each

2000 Cochrane

207. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. (Abstract)

Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. Lipoprotein(a) [Lp(a)] has been identified as an independent risk factor for coronary heart disease (CHD) events. However, few data exist on the clinical importance of Lp(a) lowering for CHD prevention. Hormone therapy with estrogen has been found to lower Lp(a) levels in women.To determine the relationships among treatment with estrogen and progestin, serum Lp(a) levels

2000 JAMA Controlled trial quality: predicted high

208. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Agrawal R, Holmes J, Jacobs H S Authors' objectives To re-analyse the results of using (...) follicle-stimulating hormone (FSH) and human menopausal gonadotropin (hMG) during in vitro fertilisation (IVF) treatment, taking into account the different protocols of administration of superactive gonadotropin-releasing hormone (GnRH) analogues (short, long protocol, or no GnRH analog). Searching The authors searched MEDLINE from January 1985 to 1999 using a combination of the keywords 'FSH', 'LH', 'hMG', 'gonadotropins', 'IVF' and 'comparison'. Review articles and abstracts of major scientific

2000 DARE.

209. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. (Abstract)

Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. The benefit of oestrogen therapy for menopause symptoms is well recognised. However, the means of delivery currently available have disadvantages, including variable bioavailability, intestinal and hepatic first-pass effects, and dermatological reactions. An intranasal 17beta-oestradiol spray, S21400, which bypasses such drawbacks, has been developed. We (...) . There was no significant difference in ear, nose, and throat function or adverse events between the S21400 and the placebo or oral oestradiol groups, except for a greater incidence of sneezing and application site reaction (99% mild or moderate) in the S21400 groups. S21400 was thought to be effective and convenient by the patients, and compliance was high.Intranasally administered 17beta-oestradiol is significantly better than placebo; its effectiveness at reducing menopausal symptoms is similar to that of oral

1999 Lancet Controlled trial quality: predicted high

210. Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women

Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Morley D C, Wheatley T Authors' objectives (...) . Studies that focused on an exercise, pharmaceutical or nutritional component without reference to an educational component were excluded. Participants included in the review Healthy post-menopausal women with untreated osteoporosis or significant osteopenia requiring health care intervention. Most of the women included in the review were aged 50-75 years. Outcomes assessed in the review All outcome measures were included, with emphasis on the following: knowledge about osteoporosis and related issues

1999 DARE.

211. Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke]

Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Oger E, Scarabin P Y Authors (...) : The authors state that only a randomised controlled trial will prove causation, rather than association, between HRT and the risk of ischaemic stroke. There is also a need to investigate the transdermal administration of HRT. Bibliographic details Oger E, Scarabin P Y. Traitement hormonal substitutif de la menopause et risque d'accident vasculaire cerebral [Hormone replacement therapy in menopause and the risk of stroke] Annales d'Endocrinologie 1999; 60(3): 232-241 PubMedID Indexing Status Subject

1999 DARE.

212. Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis

Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Macedo J M, Macedo C R, Elkis H, De Oliveira I R Authors' objectives To compare the effect of three groups of anti-resorptive drugs in post-menopausal osteoporosis. Searching MEDLINE was searched from 1983 to 1995 (keywords given). Source (...) references of retrieved articles were analysed. Study selection Study designs of evaluations included in the review Randomised controlled trials including a placebo arm, in which treatment and follow-up lasted at least a year. Specific interventions included in the review The inclusion criteria stated oestrogens, calcitonins, biphosphonates and placebo. Estradiol valerate and 17-beta-estradiol were specifically mentioned in the review. Participants included in the review Patients with post-menopausal

1998 DARE.

213. WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. (Abstract)

WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in women with clomiphene resistance WHO group 2 dysfunction undergoing ovulation induction as well as the risk of spontaneous abortion if conception takes place. Semi-purified preparations of FSH have been developed in an effort to reduce (...) the impact of exogenous LH, relatively high levels of which are present in human menopausal gonadotropin (hMG). Ovulation induction in women with clomiphene resistant WHO group 2 dysfunction who often have clinical features of polycystic ovarian syndrome (PCOS), is a major challenge. The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in this population. There also appears to be an increased risk of spontaneous abortion in those who conceive, perhaps associated

1996 Cochrane

214. Pathological complications of menopause. IPE-95/03 (Public report)

Pathological complications of menopause. IPE-95/03 (Public report) Pathological complications of menopause. IPE-95/03 (Public report) Pathological complications of menopause. IPE-95/03 (Public report) Sez A, Conde J, Ruiz F, Cuadrado C, Saiz J, Sancho J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sez A, Conde J, Ruiz F, Cuadrado C (...) , Saiz J, Sancho J. Pathological complications of menopause. IPE-95/03 (Public report) Agencia de Evaluacion de Tecnologias Sanitarias (AETS). 1995 Authors' objectives According to the recent Royal Decree (Real Decreto) which establishes the basic public coverage of health care, pathological complications of menopause must be specifically covered. The issue raised by the Ministry of Health is to establish the content of this definition and the necessity to find a specific build-up, procedures

1995 Health Technology Assessment (HTA) Database.

215. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis

Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis Daya S, Gunby J, Hughes E G, Collins J A, Sagle M A Authors' objectives To conduct a systematic overview of available data comparing follicle (...) -stimulating hormone (FSH) with human menopausal gonadotropin (hMG) in in vitro fertilisation (IVF) cycles and gamete intra-fallopian transfer (GIFT) cycles. Searching MEDLINE was searched from 1975 to 1993 using MeSH terms (terms given). Bibliographies of relevant publications and review articles were scanned and abstracts of major scientific meetings from 1983 to 1993 were handsearched. Authors of relevant abstracts were contacted as were peer reviewers. Study selection Study designs of evaluations

1995 DARE.

216. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. Full Text available with Trip Pro

Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. To evaluate the efficacy of gamolenic acid provided by evening primrose oil in treating hot flushes and sweating associated with the menopause.Randomised, double blind, placebo controlled study.District general hospital and teaching hospital.56 menopausal women suffering hot flushes at least three times a day.Four capsules twice a day of 500 mg evening primrose oil with 10 mg natural vitamin E or 500 mg liquid (...) ; the corresponding values for women taking gamolenic acid were 0.5 (0.4) and 0.5 (0.3). In women taking gamolenic acid the only significant improvement was a reduction in the maximum number of night time flushes (1.4 (0.6); P < 0.05).Gamolenic acid offers no benefit over placebo in treating menopausal flushing.

1994 BMJ Controlled trial quality: predicted high

217. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women Smith T J, Hillner B E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Adjuvant tamoxifen with or without chemotherapy for early breast cancer in pre-menopausal women. Type of intervention Secondary prevention. Economic study type Cost-effectiveness and cost-utility analysis. Study population Women aged 45 years with early breast cancer, eligible for trials of alternative cancer treatments included in the review

1993 NHS Economic Evaluation Database.

218. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. (Abstract)

Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. To elucidate the effect of smoking on estrogen metabolism, we examined 136 postmenopausal women treated for one year with one of three different doses of combined estrogen-progestogen or placebo. The women were grouped according to smoking status, and serum levels of estrone and estradiol were measured before and after treatment. The results showed reduced levels of both estrogens

1985 NEJM Controlled trial quality: uncertain